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ABSTRACT Members of the epidermal growth factor receptor family play important roles in various cellular processes, both
in physiological and in pathological conditions. Dimerization and autophosphorylation of these receptor tyrosine kinases are
key events of signal transduction. Details of the molecular events of the signaling are not entirely known. To facilitate the
understanding of receptor structure and function at the molecular level, a molecular model was built for the nearly full-length
ErbB2 dimer. Modeling was based on the x-ray or nuclear-magnetic resonance structures of extracellular, transmembrane, and
intracellular domains. The extracellular domain was positioned above the cell membrane based on the distance determined
from experimentally measured ﬂuorescence resonance energy transfer. Favorable dimerization interactions are predicted for
the extracellular, transmembrane, and protein kinase domains in the model of a nearly full-length dimer of ErbB2, which may act
in a coordinated fashion in ErbB2 homodimerization, and also in heterodimers of ErbB2 with other members of the ErbB family.
INTRODUCTION
Members of the epidermal growth factor receptor (EGFR)
family receptor tyrosine kinases play important roles in cell
proliferation, differentiation, apoptosis, and migration. The
four known members of the family: ErbB1 (EGFR), ErbB2
(HER2/Neu), ErbB3 (HER3), and ErbB4 (HER4) may act
as signal transducers at the cell membrane and initiate
a complex network of processes inside the cell in response
to extracellular signals (Marmor et al., 2004; Schlessinger,
2000; Yarden, 2001). Dysfunctions of these proteins result in
several diseases such as cancer, diabetes, immune deﬁcien-
cies, and cardiovascular diseases (Blume-Jensen and Hunter,
2001). Various approaches have been developed to thera-
peutically target ErbB proteins, including monoclonal anti-
bodies, synthetic tyrosine kinase inhibitors, toxin conjugates,
and antisense oligonucleotides (de Bono and Rowinsky,
2002).
Unlike other ErbB receptors, ErbB2 has no known ligand
(Yarden, 2001). However, its ampliﬁcation can cause breast,
ovarian, gastric, and salivary cancers (Koeppen et al., 2001;
Press et al., 1994; Slamon et al., 1987, 1989). Over-
expression of ErbB2 can occur in 25–30% of breast cancers
and correlates with an aggressive tumor phenotype (Paik and
Liu, 1999; Ross and Fletcher, 1998). An anti-ErbB2
antibody, Herceptin (Trastuzumab) (Carter et al., 1999,
1992; Ranson and Sliwkowski, 2002) is now in clinical use
against metastatic breast cancer overexpressing ErbB2;
however, 70% of patients are resistant to this treatment
(Kute et al., 2004). In contrast to Herceptin, the anti-ErbB2
antibody 2C4 is promising even in those types of cancer
where ErbB2 receptor surface density is not very high
(Jackson et al., 2004). Other approaches to break ErbB2-
mediated signaling, such as antibody-coupled cytotoxic
agents, speciﬁc small-molecule tyrosine kinase inhibitors,
antisense and interfering oligonucleotides, as well as gene
therapy, are also actively investigated (de Bono and
Rowinsky, 2002).
The ErbB receptors show close homology in their sequence
and domain organization: they have an ;600-residue-long
extracellular region with four domains responsible for ligand
binding, a single transmembrane helix, and an;500-residue-
long intracellular region with the most conserved tyrosine
kinase domain, followed by a less conserved regulatory tail at
the C-terminal end of the protein. Within a given cell type,
ErbB receptors are expressed at various levels and they can
form homo- and heterodimers or higher order oligomers at the
cell surface (Yarden, 2001). Although ErbB2 has no known
ligand, it is the most preferred oligomerization partner, and its
associated form with tyrosine-kinase-defective ErbB3 shows
the highest signal transducing potential among the ErbB
family (Citri et al., 2003). Dimerization/oligomerization plays
a critical role in the activation of the kinase domain by
bringing the two catalytic domains close enough for trans-
phosphorylation of the kinase domain itself, and further
tyrosine residues on the C-terminal regulatory domain (Vereb
et al., 2002). Recently, several structural studies on ErbB1–4
domains were published in responses to the great demand to
understand the biology of ErbB receptors: crystal structures of
extracellular domains of ErbB1 (Ferguson et al., 2003;Garrett
et al., 2002; Ogiso et al., 2002), ErbB2 (Cho et al., 2003;
Garrett et al., 2003), and ErbB3 (Cho and Leahy, 2002), and
the intracellular protein kinase domain of ErbB1 (Stamos
et al., 2002) have been determined, together with the NMR
structure of the transmembrane helix of ErbB2 (Goetz et al.,
2001).
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Fluorescence resonance energy transfer (FRET) measure-
ments are very suitable for studying conformation and asso-
ciations of biomolecules (Szo¨llo¨si et al., 2002, 1984; Tro´n
et al., 1984). FRET measurements between ﬂuorescently
labeled monoclonal antibodies on the living cells provide
useful information about proximity relationships of cell sur-
face proteins. The rate of the FRET process depends on the
inverse sixth power of the actual separation distance of donor
and acceptor dyes and on their mutual orientation factor
(Fo¨rster, 1948, 1949; Szo¨llo¨si et al., 2002). A method for
constructing two-dimensional maps of receptor distribu-
tions on the basis of FRET data was described, and maps
were constructed for major histocompatibility complex class
I and II, interleukin-2 receptor, transferrin receptor, inter-
cellular adhesion molecule-1, and ErbB receptors (Szo¨llo¨si
et al., 2002; Vereb et al., 2003).
Combinations of FRET data and molecular modeling can
provide hints about the possible orientation and arrange-
ments of membrane proteins. Previously, we have success-
fully used the same methodology to predict dimeric and
tetrameric arrangements in a supramolecular cluster of the
major histocompatibility complex class I, CD8, and T-cell
receptor localized between an antigen-presenting cell and
a T-cell (Ga´spa´r et al., 2001). In the present report we have
assembled the domains of ErbB2 with known structures to
construct a model for the nearly full-length molecule with the
help of molecular modeling methods, and have positioned
the assembled ErbB2 in the lipid bilayer of the cell mem-
brane based on FRET measurements.
MATERIALS AND METHODS
Cell lines
The human gastric cancer cell line N87 and human breast cancer cell line
SK-BR-3 were obtained from the American Type Culture Collection
(Rockville, MD) and grown according to their speciﬁcation to conﬂuency.
For ﬂow cytometry, cells were harvested by trypsin-EDTA treatment.
Fluorescent conjugation of Herceptin Fab9
The Herceptin Fab9 fragment was a kind gift of Genentech (South San
Francisco, CA). The Herceptin Fab9 was a mutated version containing an
SH-group opposite to the binding site which was conjugated with an SH-
reactive dye at 1:1 molar ratio for exact calculation of FRET distances.
Aliquots of Herceptin Fab9 (at least at 1 mg/ml concentration) were
conjugated with a maleimide derivative of ﬂuorescein (Alexa-488;
Molecular Probes, Eugene, OR) and of sulfoindocyanine (Cy3 and Cy5)
(Amersham, Brauschweig, Germany), as described previously (Szo¨llo¨si
et al., 1996).
Labeling of cells with ﬂuorescent Fab9s
Freshly harvested cells were washed twice in ice-cold phosphate-buffered
saline (PBS), pH 7.4. The cell pellet was suspended in 25 ml of PBS (ﬁnal
concentration 106 cells/sample) and incubated with 25 ml of Alexa-488-
conjugated Fab9 for 30 min on ice. The excess of Fab9 was at least ﬁvefold
above the Kd during the incubation (i.e., at saturating concentrations). The
same procedure was used for the determination of intermolecular distances
between ErbB2 molecules with Cy3- and Cy5-labeled Herceptin Fab9,
adding the same concentration of both antibodies simultaneously to the cell
pellet. Special care was taken to keep the cells on ice before FRET analysis
to avoid signiﬁcant protein internalization. The labeled cells were washed
twice with excess of cold PBS.
Labeling of cells with lipid probes
The surface of cells was labeled for FRET-based vertical distance measure-
ments with 2-(4,4-diﬂuoro-5-(4-phenyl-1,3-butadienyl)-4-bora-3a,4a-diaza-
s-indacene-3-pentanoyl)-1-hexadecanoyl-sn-glycero-3-phosphatidylcholine
(BODIPY-PC, 581/591; Molecular Probes, Eugene, OR) as acceptor for
Alexa-488-conjugated Fab9 bound to the ErbB2 receptor. For labeling with
BODIPY-PC (581/591), a ﬁnal concentration of up to 5 mg/ml of dye was
added to the cell suspension kept in glass tubes, at a cell density of 106 cells/
sample (in 50 ml ﬁnal volume). Labeling was performed for 30 min on ice,
then cells were washed twice with ice-cold PBS, labeled with Fab9 for
30 min on ice, and analyzed immediately by ﬂow cytometry. Cells were kept
in ice-cold buffer (without ﬁxation) during the ﬂow cytometric analysis.
Flow cytometric resonance energy
transfer measurements
The FRET efﬁciency was determined using ﬂow cytometry by measuring
the extent of both donor-quenching and acceptor sensitization through
detecting spectrally selected ﬂuorescence intensities on a cell-by-cell basis,
as described in details earlier (Sebestye´n et al., 2002; Szo¨llo¨si et al., 1984;
Tro´n et al., 1984). To determine the homoassociation of ErbB2 molecules,
four samples were run: 1), unlabeled cells; 2), donor-only labeled cells; 3),
acceptor-only labeled cells; and 4), donor- and acceptor-labeled cells. Single
stained samples served as controls for determining the spectral overspill of
donor and acceptor dyes, as well as nonspeciﬁc cross-excitation of the dyes
that can occur with two-laser illumination. Measurements were carried out
on a FACSCalibur ﬂow cytometer (BD Biosciences, San Jose, CA), where
dual laser excitation at 488 and 635 nm was applied to determine energy
transfer efﬁciency. Three ﬂuorescence parameters were detected simulta-
neously from each experimental sample: 1), speciﬁc donor dye ﬂuorescence
in FL2 (585/42 BP) upon 488 nm excitation (Cy3), 2), the ﬂuorescence
signal excited at 488 nm and detected in FL3 (670 LP), which in addition to
the sensitized emission of the acceptor contains spectral overlap from the
donor and from the directly excited acceptor, and 3), direct acceptor dye
emission (Cy5) in FL4 (661/16 BP) upon 635 nm excitation. The transfer
efﬁciency values (E) were determined on a cell-by-cell basis using the AFlex
software (Szentesi et al., 2004) and presented as approximately normally
distributed, unimodal energy transfer efﬁciency histograms of 20,000 cells
(Fig. 1). The mean values of energy transfer efﬁciency histograms of three
independent sets of samples were used for distance determination. In-
termolecular distances (R) were calculated using Fo¨rster’s inverse sixth-
power distance-dependence law of energy transfer efﬁciency (E) as follows:
R¼ R0(1/E-1)1/6, with a value of 5.0 nm for the R0 Fo¨rster critical distance of
the Cy3–Cy5 donor-acceptor pair (Bastiaens and Jovin, 1996).
In the case of protein/lipid FRET measurements, the ﬂuorescent proteins
are surrounded by a large array of acceptor-labeled lipids; therefore, the
efﬁciency of FRET is also a function of the donor/acceptor ratio. In such
a situation, only the perpendicular distance of labeled epitope from the cell
membrane surface is estimated according to the theory and model described
by Yguerabide (1994). The membrane proximity experiments were carried
out on a FACStarPLUS ﬂow cytometer (BD Biosciences) with 488 and
514 nm laser excitations. Three ﬂuorescence parameters were detected
simultaneously from each experimental sample: 1), speciﬁc donor dye
ﬂuorescence in FL1 (540/40 BP) upon 488-nm excitation (Alexa-488); 2),
the ﬂuorescence emission excited at 488 nm and detected in FL2 (590 LP);
and 3), ﬂuorescence emission excited at 514 nm and detected in FL4 (590 LP).
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The E-values were determined on a cell-by-cell basis using the AFlex
software (Szentesi et al., 2004). The fractional change in donor intensity,
deﬁned as E/(1-E) ¼ ID/IDA-1, was plotted against the surface density of
BODIPY-PC, and the experimental data were ﬁtted with a straight line (Fig.
2). The average of the slopes from three independent experiments was used
to determine the Kq quenching constant, from which the distance of closest
approach, R ¼ R3=20 ðp=2KqÞ1=4; was computed. The validity of the model
has been proved by Valenzuela et al. (1994) using the acetylcholine receptor
system. A value of 5.6 nm was used for the R0 Fo¨rster critical distance based
on the emission and excitation spectra of Alexa-488 and BODIPY-PC
(581/591), respectively. The surface density of BODIPY-PC was calculated
from the applied dye and cell concentrations assuming a total dye uptake by
the outer leaﬂet of the cell membrane (conﬁrmed by microscopy and
ﬂuorimetric measurement of the cells and the labeling supernatant). In our
method of calculating energy transfer, a special coefﬁcient, the so-called
a-factor, has to be used that can be determined empirically from two samples
labeled either with donor or with acceptor only, using the same antigen as the
target, expressed at high numbers at the cell surface. This approach provides
for an equal number of donor- and acceptor-bearing antibodies in the
samples, as well as good signal/noise ratio, which, with the knowledge of
dye/antibody ratios allows the placement of ET efﬁciency values onto an
absolute scale. In our case, a 1:1 donor/acceptor ratio was difﬁcult to
establish, since we were using a protein and a lipid probe and no
ﬂuorophores matching the spectral characteristics of the acceptor were
available. Therefore we used a standard (a Fab of W6/32, binding to the
heavy chain of class I HLA A, B, C molecules) with known vertical distance
from the plasma membrane (6.2 nm, Ga´spa´r et al., 2001) to calibrate our
system. A similar slope was obtained for W6/32 Fab as seen on Fig. 2 (data
not shown). Using this slope and the known distance, we derived the correct
calibrated a-factor, which in turn was used to calculate the energy transfer
efﬁciencies for the Herceptin Fab9. This approach was conﬁrmed later in an
independent experiment on a more sensitive ﬂow cytometer (FACSVantage
SE with DiVa option, BD Biosciences), when a-factor was directly
estimated and used for calculating transfer efﬁciency. The number of surface
antigens (ErbB2 receptor) was determined by a Spherotec rainbow bead with
eight ﬂuorescence peaks (G. Kisker GbR, Steinfurt, Germany). The number
of lipid probes was estimated from its surface density, which was determined
as described above. With this new, independent calibration method, we
obtained 7.7 nm for the membrane proximity of Herceptin-Fab9, which is the
same (within the error limit) as we determined with the other method using
W6/32 as a reference.
Construction of models for ErbB2 domains
Crystal structures of ErbB2 and ErbB1 ectodomains (PDB accession codes:
1N8Z, Cho et al., 2003; and 1IVO, Ogiso et al., 2002, respectively) were
downloaded from the Protein Data Bank (Berman et al., 2000). Invisible
loops were built by MODELLER (Sali and Blundell, 1993) and SYBYL
(Tripos, St. Louis, MO).
NMR structure of the transmembrane helix of ErbB2 (PDB accession
code: 1IIJ, Goetz et al., 2001) was used together with templates from the
transmembrane regions of Glycophorin A (PDB accession code: 1AFO,
MacKenzie et al., 1997), photosynthetic reaction center (PDB accession
code: 1PRC, Deisenhofer et al., 1995), and bacteriorhodopsin (PDB
accession code: 1AP9, Pebay-Peyroula et al., 1997) for construction of
transmembrane helix dimers.
The following secondary structure prediction methods were applied for
the inner juxtamembrane region, located between the transmembrane and
the protein kinase domains: GOR (Garnier et al., 1978), Maxﬁeld-Scheraga
(Maxﬁeld and Scheraga, 1976), and Qian-Sejnowski (Qian and Sejnowski,
1988) methods as implemented in SYBYL; and GOR4 (Garnier et al., 1996),
SOPMA (Geourjon and Deleage, 1995), JNET (Cuff and Barton, 1999), and
HNN (Guermeur et al., 1999), which were available on the ExPASy molec-
ular biology server (http://www.expasy.org). The ExPASy server was also
used for BLAST sequence similarity search.
The homologous model for the protein kinase domain of ErbB2 was built
by MODELLER based on the crystal structure of the protein kinase domain
of ErbB1 (Stamos et al., 2002) and the sequence alignment made by
CLUSTALW (Thompson et al., 1994).
To eliminate some large unfavorable van der Waals interactions gen-
erated by modeling, short minimizations were applied at several stages of
the procedure with the following parameters: TRIPOS force ﬁeld without
charge, 5 A˚ cutoff; 100 Simplex and 100 Powell iterations of SYBYL. All
structural calculation and visualization were done on Silicon Graphics O2 or
FIGURE 1 Representative energy transfer efﬁciency histogram of the
homoassociation of Herceptin Fab9 (bold line) and negative control of
donor-only labeled sample (thin line) on living N87 gastric tumor cells as
measured on the FACSCalibur ﬂow cytometer (BD Biosciences). To detect
homoassociation, both donor (Cy3)- and acceptor (Cy5)-labeled Herceptin
Fab’s were added simultaneously to unﬁxed cells, whereas only Cy3-
Herceptin Fab9 was added as negative control. The mean 6 SD of the
unimodal energy transfer efﬁciency distribution was used for distance cal-
culations.
FIGURE 2 Stern-Volmer plot for the determination of the distance from
the membrane of Alexa-488-labeled Herceptin Fab9 attached to ErbB2
molecules on living N87 cells. The derived E/(1-E) values are plotted against
the surface density of our lipid probe, BODIPY-PC (581/591) used as
a FRET acceptor. The experimentally determined points, obtained from
means of energy transfer efﬁciency histograms, were ﬁtted with a straight
line, whose slope was used to determine membrane proximity of the
Herceptin Fab9 (for details, see Materials and Methods). The plot is re-
presentative of three similar measurements.
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Fuel graphical workstations. Coordinates of the models are available upon
request from the authors.
RESULTS AND DISCUSSION
Several structural studies on separate domains of ErbB1-4
receptors were published recently, but it is still not known in
molecular detail how ligand binding to the ErbB receptors
leads to signal transduction. In this report we propose a model
for a nearly full-length ErbB2 dimer, built by using FRET
measurements, crystal structures of ErbB ectodomains, and
molecular modeling methods. This model may supplement
recent structural views (Burgess et al., 2003) to elucidate the
molecular events of the ErbB signal transduction pathways.
Estimation of intermolecular epitope distances
of ErbB2 molecules on N87 cells by
FRET measurements
Homoassociation of ErbB2 molecules was determined by
FRET measurements where Cy3- and Cy5-conjugated
Herceptin Fab9 fragments were applied as a donor-acceptor
pair. In the Fab9 molecules, the localization of the
ﬂuorophore was predetermined by an SH group introduced
at the end distal from the antigen recognition site of the Fab9.
The antibody fragments carried one ﬂuorophore per
molecule on average with a high degree of motional freedom
allowing a dynamic orientational averaging. This condition
allows a reasonable distance estimation from FRET
efﬁciencies, since the statistical average of the orientation
factor (otherwise also inﬂuencing FRET efﬁciency), k2 ¼
2/3, is a good approximation for this case. The FRET
efﬁciency histograms constructed from cell-by-cell ﬂow
cytometric measurements (Fig. 1) show positive FRET
efﬁciency for ErbB2 homoassociation on both cell lines
(N87 and SK-BR-3), which differs signiﬁcantly from the
negative control, i.e., from the FRET efﬁciency distribution
of the sample labeled with donor only. FRET analysis
provided similar data for N87 and SK-BR-3 cells, but the
expression level of ErbB2 was higher (30% more) on N87
than on SK-BR-3, thus only the data obtained on N87 cells
are shown and used in this article. The FRET efﬁciency
value (11.2 6 0.9% being the mean 6 SD of histogram
means from three independent measurements) was converted
to molecular distances, as described in Materials and
Methods. The intermolecular distance of Herceptin Fab9 on
ErbB2 is 7.1 6 0.2 nm, reﬂecting a close association of
ErbB2 molecules on living N87 gastric carcinoma cells.
Similar results were reported previously (Nagy et al., 1998,
2002), where whole IgGs were applied.
The distance of anti-ErbB2 Herceptin Fab9 from
the plasma membrane
To determine the proximity of the ErbB2 ectodomain to the
cell membrane, FRET experiments were performed with
Alexa-488-labeled Herceptin Fab9 (with known docking site
to the receptor) as a donor, and a lipid probe BODIPY-PC
(581/591) as an acceptor with varying concentration and
surface density. In addition, to verify our method for
establishing proximities to the cell membrane, we also
used a lipid probe (Cy5-DSPE) as a negative control, which
only minimally enters the GM1-rich microdomains where
ErbB2 is mostly localized, and obtained no considerable
energy transfer efﬁciency values (2% with the highest
concentration). The mean values of FRET efﬁciency
distribution histograms were plotted as a function of lipid
probe density and vertical distance from the membrane was
derived from the slope of the ﬁtted line, according to
Yguerabide (1994) (Fig. 2). The ﬂuorescently-labeled end
part of Herceptin Fab9 had a closest approach distance of
7.5 6 0.6 nm as a mean 6 SD of three independent
measurements. In the consequent molecular modeling, this
distance estimate, measured on living cells, was used for
steric positioning of the x-ray-resolved ErbB2 structures
relative to the surface of the plasma membrane. Since we
used a relative approach to determine the membrane
proximity, the accuracy of the results might be in question.
One source of uncertainty in the measurement of distance
from the membrane is the calculation of surface concentra-
tion of the lipid probe. This calculation assumes perfectly
spherical cells, although in reality the membrane is not even.
Therefore the calculated surface concentration can be
considered as the upper limit, and the true concentration of
probe in the membrane should be more or less smaller,
depending on the type of cells used in the experiments. The
cells utilized in our experiments have a fairly smooth surface
and, based on the good agreement of distances determined
by two independent methods, the perfect sphere approxima-
tion appears to be a valid approach in this case. However, in
the case of cells having substantially more uneven surfaces
(e.g., macrophages), the distance obtained from the FRET
measurement would be more overestimated and should be
considered only as an upper limit of the distance. Since
the region of the ErbB2 connecting the ectodomain with the
transmembrane domain is quite ﬂexible, the distance value
measured for membrane proximity has little inﬂuence on our
model calculations.
Construction of the model of ectodomain dimer
of ErbB2
Chemical crosslinking experiments showed that ErbB1
formed a dimeric structure on the surface of living cells to
some extent, without a bound ligand (Chu et al., 1997;
Moriki et al., 2001). Partially puriﬁed ErbB1 was resolved in
a sucrose density-gradient as mostly dimers in the presence
of a low concentration of detergent (Moriki et al., 2001).
Artiﬁcially mutated ErbB1 receptors containing Cys in the
extracellular juxtamembrane region also showed a high
tendency for dimerization (Moriki et al., 2001; Sorokin et al.,
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1994). In situ FRET measurements on A431 epidermoid
carcinoma cells conﬁrmed the existence of preformed ErbB1
dimers in the cell membrane (Gadella and Jovin, 1995).
Based on similar experiments on other ErbB molecules
(Burke and Stern, 1998, Nagy et al., 1998, 2002), Moriki
et al. (2001) assumed that the tendency for dimerization is
valid not only for ErbB1, but also for other homologous
members of ErbB family.
Our model-building procedure for ErbB2 dimer started
with the extracellular domains of ErbB2. It was assumed that
the ErbB2 dimer could adopt a conformation similar to that
of the ErbB1 dimer in the crystal form (Ogiso et al., 2002).
The fact that all kinds of homo- and heterodimerization can
be seen among the members of the ErbB family (Yarden,
2001) and the similarities of the sequences and the structures
of the dimerization arms of ErbB1–4 molecules, support this
hypothesis. However, no such dimer formed during
crystallization of the ErbB2 ectodomain (Cho et al., 2003;
Garrett et al., 2003), which may suggest that interaction
between ectodomains of ErbB2 is rather weak (Burgess et al.,
2003). Also, although no homodimerization of the extracel-
lular domains of ErbB2 was detected by sedimentation
equilibrium analytical ultracentrifugation and multi-angle
laser-light scattering, there was evidence for a weak ligand-
induced heterodimerization with the extracellular domain of
ErbB3 and ErbB4 (Ferguson et al., 2000). It was suggested
by Garrett et al. (2003) that the ErbB2 ectodomain could not
form a dimer similar to ErbB1 on its own, but multiple
interactions could contribute to receptor association on the
surface of living cells. However, ﬂow cytometric resonance
energy transfer measurements on living N87 cells showed
some degree of ErbB2-ErbB2 ectodomain homoassociation:
reproducible signals were measured between two differently
labeled Herceptin Fab’s, which can bind only to identical
epitopes in the S2 domain of two ErbB2 ectodomains
(Cho et al., 2003). Crystallographic analysis suggests that
inhibition of signal transduction caused by Herceptin is
not originated from a large structural change of ErbB2
ectodomain: uncomplexed human ErbB2 (Garrett et al.,
2003) and rat ErbB2 (Cho et al., 2003) fragments form
structures very similar to the Herceptin-complexed human
ErbB2 (Cho et al., 2003) ectodomain.
There are four nonvisible loops in the crystal structure of
ErbB2 ectodomain complexed with Herceptin Fab9 (Cho
et al., 2003). Two of them (Ala302–Thr306 and Asp360–
Ser365) were modeled based on the homologous regions of
the ErbB1 ectodomain (Ogiso et al., 2002). Another two
loops (Leu101–Ser111 and Ser580–Ile591) were built by the
Protein Loop Search algorithm of SYBYL. Two copies of
this ErbB2 model complexed with Herceptin Fab9 were
aligned to the crystal structure of the ErbB1 dimer (Ogiso
et al., 2002) A- and B-chains, respectively, and the
conformations of the dimerization loops (Cys246–Arg266)
were changed to those found in the ErbB1 dimer by
MODELLER (Sali and Blundell, 1993). The alignment
regions consisted of residues only from S1 domains
(dimerization loops were also excluded), since different
relative position of L- and S-domains in ErbB1 and ErbB2
may result in bad ﬁtting of the two monomers (Fig. 3). Small
bumps remained between the Herceptin Fab9 bound to the S2
domain of one monomer and the L2 domain of the other
monomer, therefore c-torsional angles of Gly484 and Glu485
were changed from 331.5 to 335 and from 353.5 to 350,
respectively, in the ﬂexible linker region between the L2 and
S2 domains. To eliminate some large unfavorable van der
Waals interactions generated by modeling, a short minimi-
zation was applied to the whole dimer. The dimer was trans-
lated and rotated to the center of the coordinate system in such
a way that the C2 symmetry axis of the dimer was in line
with the z axis and the x,y plane served as amodel for the outer
surface of the cell membrane.
Although this dimer conﬁguration appears to be a good
candidate based on the analogy to the ErbB1 homodimer, it
should be noted that other conﬁgurations for the ErbB2
homodimer should also exist so that the experimentally
measured 7.1 nm intermolecular distance between bound
Herceptin Fab9, which is substantially smaller than the 12.3
nm implied in the model, can also be satisﬁed. This 7.1 nm
distance can be conceived as a weighted average from di-
mers predicted by the model and other dimers (or higher
oligomers) that, themselves, would yield smaller intermo-
lecular distances. Therefore it is predicted that the modeled
FIGURE 3 Ribbon models of superimposed ErbB1 (solid ribbon) and
ErbB2 (shaded ribbon) ectodomains. Ca atoms that served as seed atoms for
superposition are shown in space-ﬁll representation in both structures.
Domain names (L1, S1, L2, and S2) and approximate domain positions
(broken lines) are shown only in one monomer.
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ErbB1-like dimer conﬁguration exists as a subclass among
many others, and/or as a dynamic entity that could be inter-
converted to other dimeric forms. Sequence and structural
differences between ErbB molecules may result in different
levels of stabilization of various dimer forms that could exist
at the same time.
Construction of the model for the transmembrane
helix dimer of ErbB2
Besides the possible dimerization of ErbB2 ectodomains, the
transmembrane domain can also dimerize, as supported by
experimental data (Mendrola et al., 2002; Sharpe et al.,
2002). Transmembrane a-helix pairs from membrane
proteins with resolved structures served as a template for
constructing the dimer of ErbB2 transmembrane domain.
Two copies of the NMR structure of the transmembrane
helix of ErbB2 (Goetz et al., 2001) were aligned to each
helix-pair template and a short minimization was applied for
each dimer of helices. The helix dimer which was based on
helices 3 and 5 of the photosynthetic reaction center showed
better agreement with requirements of the GxxxG dimeriza-
tion motif and the models described previously (Fleishman
et al., 2002; Gerber et al., 2004; Kim et al., 2003; Mendrola
et al., 2002; Moriki et al., 2001); therefore it was chosen for
further manipulation (Fig. 4).
The helix dimer was positioned below the ectodomain
dimer. The ectodomain dimer and the transmembrane dimer
were put in the same rotational axis, therefore each dimer
interface could enhance the effect of the other dimerization
region. More than one dimerization interface, acting syner-
gistically, may help the formation of tightly bound ErbB2
dimers or heterodimers with other members of the ErbB
family and may help to ﬁnd the correct position of kinase
domains for transphosphorylation.
Construction of the model for the extracellular
dimer of ErbB2
The distance between the ectodomain and the membrane was
set based on FRET measurements: the ectodomain dimer
complexed with Herceptin Fab9 was moved up along the z
axis until the vertical distance of the free end of the Herceptin
Fab9 from the cell membrane (x,y plane) reached the
experimental value determined by FRET. The transmem-
brane helix dimer was moved down along the z axis until the
N-terminal hydrophobic segment of the helices reached the
x,y plane. The Protein Loop Search algorithm of SYBYLwas
applied to ﬁll the gap between the C-terminal end of the
ectodomain and the N-terminal end of the transmembrane
domain. To satisfy the symmetry requirements of the
structure, one monomer containing the full extracellular and
transmembrane domains was duplicated and aligned to the
other monomer, which was deleted after the transformation
(Fig. 5). Short minimization was applied for the new dimer.
FIGURE 4 Front view (A) and side view (B) of the line ribbon model of
transmembrane helix dimer. The outermost residues of theGxxxGmotifs are
shown in ball-and-stick representation in both monomers.
FIGURE 5 Ribbonmodel of the extracellular and transmembrane domains
of ErbB2 (solid ribbon) complexed with Herceptin Fab9 (shaded ribbon).
Arrows represent the distance of the end-labeled Herceptin Fab9 from the
outer surface of the membrane (horizontal line) determined by FRET.
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TheC-terminal part of the S2 domain is not ordered, or does
not exist in crystal structures of ErbB molecules (Cho and
Leahy, 2002; Cho et al., 2003; Ferguson et al., 2003; Garrett
et al., 2003, 2002; Ogiso et al., 2002), andmay form a ﬂexible
arm together with the outer juxtamembrane region, as shown
for the juxtamembrane region of ErbB1 (Moriki et al., 2001).
The ﬂexibility of this region may be required in dimer
formation for the correct positioning of the ﬁrst monomer
(ErbB2) relative to the variable second monomer (ErbB1–4).
Our ﬂexible model does not rule out the possibility of
interaction between S2 domains of homo- or heterodimers
of ErbB molecules, as suggested by immunoprecipitation
(Kumagai et al., 2003) and mutational studies (Siegel and
Muller, 1996), and this possibility may also be valid for the
linker regions.
Construction of the model for the intracellular
dimer of ErbB2
Secondary structure of the juxtamembrane region located
between the transmembrane and the protein kinase domains
was predicted by several methods of SYBYL or of the
ExPASy molecular biology server (http://www.expasy.org).
All prediction methods showed high probability of a-helix
for the N-terminal half of the sequence (Fig. 6).
Sequence similarity search against the Protein Data Bank
was applied using the BLAST program of the ExPASy server.
The top two hits were 1ETE and 3HLA. Both of them showed
an elbowlike structure with an a-helical region on one side
and an extended conformation on the other side. However, the
a-helical region of the 1ETE fragment was located on the
C-terminal, whereas the a-helical region of 3HLA fragment
was located on the N-terminal part of the structure. The
proximity of the a-helical transmembrane segment together
with the consensus result of several secondary structure
prediction methods and the three-dimensional structure of the
3HLA fragment suggested that this 3HLA fragment may
serve as a good template for homologous modeling of the
inner juxtamembrane region of ErbB2. The homologous
model (Fig. 7) was built by MODELLER.
The inner juxtamembrane region seemed to be more rigid
than the outer juxtamembrane region, which may help to
transfer the molecular movement of the transmembrane
domain toward the kinase domain. Rotational coupling of the
transmembrane domain and kinase domains was shown
experimentally for ErbB1 (Moriki et al., 2001) and ErbB2
(Bell et al., 2000).
Two copies of the model of the juxtamembrane segment
were superimposed with the modeled transmembrane helix
dimer using the four N-terminal residues, which were
common in the models of the juxtamembrane region and the
transmembrane helix. Model building was continued with the
superposition of two copies of the protein kinase domain
using the common four terminal residues. Interestingly, using
this approach, the two kinase domains formed a good,
symmetric back-to-back dimer without any unfavorable
interaction (Fig. 8, A and B). A short minimization procedure
was applied for the whole intracellular dimer as previously
done for the extracellular dimer.
In our model the localization of the kinase domain was
designated solely based on the position of the transmem-
brane domain dimer and the shape of the model of the inner
juxtamembrane region. Based on the model, kinase domains
may interact and may serve as a third dimerization interface.
FIGURE 6 Secondary structure prediction of inner juxtamembrane region
of ErbB2 using different methods. Only a-helical (A) and b-sheet (B) states
are shown.
FIGURE 7 Homologous model of the inner juxtamembrane region of
ErbB2.
FIGURE 8 Front view (A) and side view (B) of the ribbon model of the
transmembrane and the intracellular domains of the assumed ErbB2 dimer.
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The interaction of kinase domains is also supported by ex-
perimental data (Penuel et al., 2002).
We searched PDB for similar conﬁgurations of protein
kinase dimers, but there were none in which the two
monomers occupied the same relative position as in our
model. We also checked the other four transmembrane helix
dimers which were neglected previously. If the trans-
membrane region and the kinase domain were linked with
the same elbowlike structure, they resulted in too close or too
distant kinase domains, which were unable to interact with
each other in the dimer conﬁguration.
Construction of the nearly full-length model for
the ErbB2 dimer
The models of the extracellular dimer and intracellular dimer
were superimposed based on the common transmembrane re-
gions. This nearly full-length ErbB2 dimer consisted of the
whole ectodomain, the outer juxtamembrane region, the trans-
membrane domain, the inner juxtamembrane region, the pro-
tein kinase domain, and a part of the regulatory C-terminal
tail of the ErbB2 molecule (Fig. 9).
We have built an ErbB2 homodimer structure with three
potentially interacting regions. This ErbB2 homodimer,
taking into account the similar structures of the ligand-
bound forms of the other ErbB molecules, may serve as
a starting model for heterodimers of ErbB2 with other
members of the ErbB family. It should be noted that even
higher levels of associations might be required for signal
transduction through the ErbB receptors. The back-to-back
kinase dimer arrangement could be responsible for the
transphosphorylation of the cytoplasmic regulatory tails but
not of the kinase domains themselves, which requires the
involvement of other kinase molecules.
CONCLUSION
Here we report a procedure that combines existing crystal
structures, NMR data, and FRET measurements with
molecular modeling to predict an almost full-length
monomeric, as well as possible dimeric forms for ErbB2
(and other ErbB) receptors. It should be emphasized that our
predicted ErbB dimer structure could be just one of the
several possibilities that may exist on the surface of a living
cell: other types of dimer conﬁgurations should exist which
satisfy the FRET distance criteria alone, or in combination.
The resolution of our model is not aimed to reach the
resolution of the initial crystal structures, especially not in
the linker regions and at the dimer interfaces, but it may
serve as a working hypothesis and may initiate experiments
to conﬁrm or reject it. A crucial part of our modeling was the
incorporation of FRET data obtained on live cells into the
construction of the nearly full-length ErbB2 model.
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